Paxil is a suitable prescription for depression in adults over the age of 18, as it has gained United States Food and Drug Administrations approval for this use. Paxil has not yet been approved by the FDA however for children and teenagers under the age of 18 as it has been shown that Paxil Can Cause Neonatal Abstinence Syndrome. In one particular case study however, there has been seen that the manufacturer of Paxil, GlaxoSmithKline, has tampered with case study results with regards to the drugs safety and efficacy.

This particular study which is named Paxil Study 329, was published in the Journal of the American Academy of Child and Adolescent Psychiatry in 2001. It claimed that Paxil was good for treating depression in kids and that patients didn't suffer many adverse effects from taking the drug. This information can be misleading however as more recent studies have shown that Paxil actually has the potential to raise suicidal tendencies in children by as much as 5%.

An additional problem that has been seen in this study is that the authors whose names that have been placed on this particular study were not the ones who wrote the results. The study was actually ghost written. A ghost writer means that another writer was paid to write and publish the results using the other authors names. This could be a sign that the authors whose names appear on the study may not have known the information contained in the study itself.

What can be seen as the most concerning problem with study 329, however, is the fact that the researchers who handled this study carefully picked over the data to present only the data in the published study that were most favorable to the drug that paid for the study. This is a concern for many because if the researchers involved with this study conceal the true design of a study or negative results, then journals will not be able to get the complete picture. Meaning the medical journals publish such a picture not knowing the whole truth.

The results that were published of Paxil Study 329 have been found to be misleading to the public; and have been the grounds leading to several Paxil Birth Defect Lawsuits. Paxil has yet to gain FDA approval for use with children and teenagers under the age of 18.